Oslo, 12 August 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) on 9 July 2024 regarding the final result of the rights issue, raising gross proceeds of NOK 18,107,480. In association with the rights issue transaction, Atlas guaranteed for NOK 10 million under the existing convertible bond facility to ensure minimum NOK 19.395 million in gross proceeds (the “CB commitment”). As the rights issue subscriptions fell below the secured minimum level, Circio has by a notice of exercise, formally called on the CB Commitment by requesting Atlas to subscribe and pay for three convertible bonds with an aggregate principal amount equal to NOK 1,500,000. Atlas will be allocated these bonds under the terms and conditions of the Investment Agreement.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.